This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep 2026 quarter: revenue down 14.8%, profit after tax turns to a loss of Rs 57.19 lakh
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.8 pts less than Nifty Microcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended 30 September 2026: revenue from operations was Rs 3,934.99 lakh versus Rs 4,617.13 lakh a year earlier, down 14.8%; profit after tax was a loss of Rs 57.19 lakh versus a profit of Rs 221.25 lakh. Derived EBITDA margin fell from 9.2% to 1.8%. Standalone half year ended 30 September 2026: profit after tax was Rs 147.32 lakh versus Rs 468.75 lakh in the prior-year half year. No consolidated results were reported.
Quarterly loss and margin compression are negative, though the half-year stayed profitable; earnings pressure may weigh on the stock.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹39.35 Cr | ₹46.17 Cr | −14.8% |
| Operating profit | −₹1.13 Cr | ₹2.38 Cr | −147.3% |
| Profit after tax | −₹0.57 Cr | ₹2.21 Cr | −125.8% |
| EBITDA margin | 1.8% | 9.2% | −7.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.